Changes in Beneficial Ownership · 4
First Tracks Biotherapeutics, Inc.
TRAXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-08182026_040802.xml
Filing details
- Report period
- 2026-08-15
- Issuer
- First Tracks Biotherapeutics, Inc.
- Issuer CIK
- 0002091349
- Trading symbol
- TRAX
Reporting owner 1
- Name
- Faga Daniel
- Reporting owner CIK
- 0001673528
- Relationship
- Director · Officer
- Officer title
- President, CEO
- Address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Units[F1] | [F2] | 2026-08-15 | A · Form 4 | 193,575 | A | 0 | [F3] | [F3] | Common Stock | 193,575 | 440,485 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026.↩ 1
- F2
- Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.↩ 1
Signature 1
- Signed
- /s/ Ajim Tamboli, Attorney-in-Fact
- Date
- 2026-08-18
Company context
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.